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ABSTRACT
Genomic gain of the proto-oncogene transcription factor gene MYCN is associated 
with poor prognosis in several childhood cancers. Here we present a comprehensive 
copy number analysis of MYCN in Wilms tumour (WT), demonstrating that gain 
of this gene is associated with anaplasia and with poorer relapse-free and overall 
survival, independent of histology. Using whole exome and gene-specific sequencing, 
together with methylation and expression profiling, we show that MYCN is targeted 
by other mechanisms, including a recurrent somatic mutation, P44L, and specific 
DNA hypomethylation events associated with MYCN overexpression in tumours with 
high risk histologies. We describe parallel evolution of genomic copy number gain 
and point mutation of MYCN in the contralateral tumours of a remarkable bilateral 
case in which independent contralateral mutations of TP53 also evolve over time. 
We report a second bilateral case in which MYCN gain is a germline aberration. Our 
results suggest a significant role for MYCN dysregulation in the molecular biology of 
Wilms tumour. We conclude that MYCN gain is prognostically significant, and suggest 
that the novel P44L somatic variant is likely to be an activating mutation.
INTRODUCTION
Wilms tumour (WT, nephroblastoma) is the 
commonest paediatric renal malignancy. A significant 
minority of WT cases have mutations in known genes, 
including WT1 [1-6], CTNNB1 [7, 8], AMER1 (WTX) 
[9], and TP53 [10]. Less frequent mutations targeting 
genes such as FBXW7 [11] and GPC3 [12] have also 
been reported, and epigenetic lesions affecting the IGF2/
H19 locus are common [13]. A recent whole exome 
study has indentified mutations in microRNA processing 
genes including DROSHA, DGCR8 and DICER1 [14]. 
Numerous recurrent copy number aberrations and loss 
of heterozygosity (LOH) events have been described, 
some of which affect known genes (e.g. 11p LOH, 17p 
loss, focal deletion of AMER1 and FBXW7), while the 
functional significance of others (e.g. 1q gain, 1p loss, 
16q loss) is unclear. Only a few of these aberrations have 
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known associations with histology or outcome. TP53 
mutations are largely confined to (high risk) anaplastic 
tumours [10], while WT1 mutations (which are frequently 
coincident with CTNNB1 mutations) are associated with 
stromal predominant histology [15]. We have previously 
noted an association between 1q gain and relapse [16, 17], 
but the only genomic biomarker with a fully validated 
association with poor outcome that is currently used in 
treatment planning is simultaneous loss of heterozygosity 
of 1p and 16q [18].
One recurrent focal copy number gain on 2p24.3, 
encompassing the MYCN locus, has been observed in 
several previous WT studies [11, 19-23]. The MYCN gene 
encodes a proto-oncogenic MYC family transcription 
factor, MYCN. MYCN is known to be amplified in 16-
25% of neuroblastomas, an aberration associated with a 
poorer prognosis, and it undergoes prognostically relevant 
copy number gain, and more rarely amplification, in other 
paediatric tumours including medulloblastoma [24, 25] 
and rhabdomyosarcoma [26]. In an earlier study [11], we 
used SNP arrays to analyse tumours from patients who had 
received pre-operative chemotherapy under International 
Society of Paediatric Oncology (SIOP) protocols, and 
noted an apparent association between MYCN gain and the 
high risk diffuse anaplastic subtype. In a larger study [22], 
in which genomic real-time PCR was used to measure 
MYCN copy number in a more heterogenous group of 
tumours from patients treated under various protocols 
(including immediate nephrectomy), we confirmed that 
MYCN gain is a common event, but found no particular 
subtype association. In the current report, we describe 
the largest analysis of MYCN status in WT to date, using 
multiplex ligation dependent probe amplification (MLPA) 
to assess its copy number in a series of samples drawn 
entirely from the SIOP WT 2001 clinical study and trial.
Recent developments in neuroblastoma genomics 
suggest that gain or amplification is not the only 
mechanism that affects MYCN function in paediatric 
tumours. Maris and co-workers, using whole genome 
sequencing, have shown that a specific somatic variant, 
P44L, can be detected in 2% of all neuroblastomas 
analysed [27], while isolated cases of the same variant 
have also been described in glioma, medulloblastoma, 
endometrial carcinoma, and neoplastic cysts of the 
pancreas [28-31]. This variant is postulated to be an 
activating ‘gain of function’ mutation that, like increased 
MYCN dosage due to copy number gain, could cause 
oncogenic upregulation of downstream MYCN-dependent 
pathways. 
Here we report the discovery of MYCN P44L 
mutations through whole exome analysis of Wilms 
tumour, leading us to hypothesise that multiple routes to 
MYCN-oncogenesis may exist in this paediatric tumour. 
We present targeted MYCN sequencing analysis of a large 
WT series to determine the frequency of these mutations, 
and investigate potential correlations between MYCN 
expression levels, copy number events, and gene-specific 
hypomethylation.
RESULTS
Point mutations in the MYCN coding sequence
In a whole exome analysis of a series of 51 WTs, 
enriched in cases with high risk histology or poor outcome, 
heterozygous somatic point mutations in the MYCN coding 
sequence were detected in three tumours. In all three 
cases, the same variant, a c.131C>T transition substituting 
proline with leucine at codon 44 (p.P44L), was detected 
(Table 1). 45 of the 51 cases gave informative exome 
data at this position, with sufficient depth of coverage 
for variant calling. Thus, 6.7% of the cases that could 
be analysed in the exome series carried this mutation. 
To determine the proportion of WTs harbouring this or 
other MYCN mutations in a larger, unselected cohort 
(Supplementary Table 1), we sequenced the complete 
MYCN coding region in 168 additional tumour samples. 
Where a mutation was detected, we sequenced matched 
normal kidney or blood germline DNA (if available) from 
the same case. Five additional tumours carrying P44L 
were identified (3.0%, Table 1) and, as in the exome 
series, all mutations were heterozygous in the tumour 
and absent from the germline. The overall frequency of 
P44L in the extended series of 213 cases was therefore 
3.8%. The subset carrying the mutation had no particular 
distinguishing features. Multiple histological subtypes 
(as defined by SIOP) and clinical stages were represented 
(Table 1). Only one of the patients – the complex bilateral 
case described in Table 2 and below - has so far suffered 
a recurrence (minimum follow-up 25 months, median 
follow-up 54.5 months), and none have died.
Four further non-synonymous heterozygous variants 
elsewhere in the MYCN coding sequence, each affecting 
a single case, were also found (Table 1). The first of 
these, c.853C>T (p.R285W), was present in the germline. 
R285 is a highly conserved amino acid residue in protein 
domain pfam01056 (‘Myc amino-terminal region’ [32]). 
This mutation was predicted as damaging by both SIFT 
[33] and PolyPhen2 [34]. The second variant, c.227G>A 
(p.S76N), was found in a case for which no blood or 
unambiguous normal kidney tissue was available, so it was 
not possible to determine if it was a germline variant. S76 
is a poorly conserved residue, and the S76N variant was 
not predicted as damaging by either SIFT or PolyPhen. 
A third variant, c.473C>T (p.A158V), was located in 
another poorly conserved region and predicted as tolerated 
by SIFT, but possibly damaging by PolyPhen, and was 
confirmed as present in the germline. The fourth variant, 
c.1093C>G (p.P365A), was also predicted to be a benign 
change by both algorithms, and is a known rare variant 
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previously observed in the 1000 Genome Project data 
[35]. Data from unambiguous germline material were not 
available. No congenital abnormalities or family history 
of cancer were reported in three of these cases; no data 
were available for the A158V case. Two further variants 
(c.189C>A, c.207G>A), one of which was a rare known 
SNP, were also identified in three samples (Table 1), but 
they did not alter the amino acid sequence or overlap with 
splice sites and were not analysed further. 
MLPA copy number analysis of all the cases with 
Figure 1: Focal gain of MYCN in the germline of a bilateral WT case. (a) Illumina CytoSNP-12 raw copy number data (Log R 
Ratio) from blood sample ICH-10529 showing probes aligned to the 2p region. (b) Copy number segmentation by OncoSNP (linear scale). 
Arrows: position of region of focal gain. LOH = segmented loss of heterozygosity (none detected).
Table 1: MYCN single nucleotide variants in Wilms tumour.
ICH ID Exome Genomic (Chr2) CDS Protein Germline ESP5400 1000g dbSNP 132 SIFT
P o l y -
Phen2 Histology Stage MYCN CN
2560
Y g.16082317C>T c.131C>T p.P44L Wild type    D D Focal Anaplastic 3 Normal
3863
Y g.16082317C>T c.131C>T p.P44L Wild type    D D Regressive 1 Normal
4788
 g.16082317C>T c.131C>T p.P44L Wild type    D D Regressive 3 Gain
4956
 g.16082317C>T c.131C>T p.P44L Wild type    D D Regressive 2 Normal
6613
 g.16082317C>T c.131C>T p.P44L Wild type    D D Mixed 1 Gain
8783
Y g.16082317C>T c.131C>T p.P44L Wild type    D D Blastemal 2 Normal
8819
 g.16082317C>T c.131C>T p.P44L Wild type    D D Regressive 3 Gain
9750
 g.16082317C>T c.131C>T p.P44L Wild type    D D Mixed 1 Normal
3136
 g.16085677C>T c.853C>T p.R285W Variant    D D Stromal 1 Normal
4692
 g.16082413G>A c.227G>A p.S76N N/A    T B Regressive 3 Normal
7512
 g.16082659C>T c.473C>T p.A158V Variant    T P Stromal 2 Gain
9431
 g.16085917C>G c.1093C>G p.P365A N/A 0.0005 0.0005  T B Regressive 3 Normal
8914
 g.16082375C>A c.189C>A p.P63P ND    - - Mixed 1 Gain
9140
 g.16082393G>A c.207G>A p.E69E ND 0.0027 0.0009 rs41264199 - - Regressive 1 Normal
9224
 g.16082393G>A c.207G>A p.E69E ND 0.0027 0.0009 rs41264199 - - Regressive 1 Normal
SIFT/PolyPhen2: D = damaging, T = tolerated, B = benign, P = possibly damaging. 1000g = variant frequency in 1000 
Genome Project (Feb 2012). ESP5400 = variant frequency in Exome Sequencing Project (Dec 2011). N/A = material not 
available. ND = Not done.
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Table 2: MYCN and TP53 aberrations in a bilateral WT case.
ICH 
ID Side Sample Histology TP53 MYCN seq data
MYCN 
CN
Other 
aberrations
Treatment 
Month
5179  Blood  wild type wild type NA NA  
3474 Left Initial biopsy Wilms tumour wild type ND Gain +1q, +6, +8, -10p, +12p, +13, -20p 1
6583 Left Partial nephrectomy
Wilms tumour 
(stromal area) wild type wild type NA NA 6
6580 Left Partial nephrectomy
Wilms tumour 
(anaplastic area)
c.517G>T: 
p.173V>L wild type NA NA 6
3864 Left Partial nephrectomy
Wilms tumour 
(diffuse anaplastic)
c.517G>T: 
p.173V>L wild type Gain
+2, +6, -10p, +13, 
-14q, -17p, +17q, 
-20p
6
3865 Left Partial nephrectomy
Wilms tumour 
(diffuse anaplastic)
c.517G>T: 
p.173V>L wild type Gain
+2, LOH 6, +8, 
-10p, +10q, +13, 
-17p, +17q, -20p
6
6579 Left Partial nephrectomy Normal kidney wild type wild type NA NA 6
6578 Left Partial nephrectomy Nephrogenic rest wild type wild type NA NA 6
3475 Right Initial biopsy Wilms tumour wild type wild type Normal Neutral profile 1
6581 Right Partial nephrectomy
Wilms tumour 
(regressive) wild type c.C131T:p.P44L NA NA 6
3863 Right Partial nephrectomy
Wilms tumour 
(regressive) wild type c.C131T:p.P44L Normal +1q, LOH 14 6
6582 Right Partial nephrectomy Normal kidney wild type wild type NA NA 6
9934 Right Partial nephrectomy Nephrogenic rest n/a wild type NA NA 6
8426 Right Recurrence Wilms tumour (diffuse anaplastic)
c.584T>C: 
p.I195T wild type NA NA 54
NA = Data not available
Figure 2: Copy number heterogeneity in a bilateral WT case. Affymetrix SNP 6.0 smoothed log2 ratios. (a) ICH-3474 (left, 
initial biopsy). (b) ICH-3864 (left, partial nephrectomy sample 1). (c) ICH-3865 (left, partial nephrectomy sample 2). (d) ICH-3475 
(right, initial biopsy). (e) ICH-3863 (right, partial nephrectomy). Arrows: position of MYCN gain. x-axis: genomic position (divided by 
chromosome). y-axis: relative copy number (log2 scale). Known copy number variants detected by CNV-specific probes on the SNP 6.0 
array were not excluded from this analysis, and are visible as multiple focal peaks in all profiles; the most prominent peak on 2p, labelled 
‘*’ in panel (a), corresponds to the variable ANKRD36BP2 locus, and should not be confused with the MYCN peak. 
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MYCN sequence variants (as below) showed that three 
of the eight P44L tumours (ICH-4788, 6613 and 8819) 
also had evidence of MYCN gain, while single control 
probes on 2p (DYSF) and 2q (PAX3) detected normal copy 
number, indicating a focal or regional event rather than 
whole arm or chromosome gain. ICH-7512, the A158V 
case, had large scale or complete gain of chromosome 2, 
as did one of the samples with a silent mutation, ICH-
8914. 
Germline MYCN gain in a bilateral WT case
In a SNP array analysis of a bilateral case, a 
relatively focal single copy gain of MYCN was detected 
in both contralateral tumours. To determine if this was a 
germline aberration, or a somatic change (an early event 
in kidney development or a contralateral metastasis), 
copy number profiles were also obtained from the (right) 
normal kidney and the patient’s blood DNA. Both samples 
harboured the region of gain, confirming that this was a 
germline event. Segmentation of the copy number data 
with OncoSNP detected a <0.5 Mb region of single copy 
gain (Figure 1, Supplementary Figure 1), spanning 98 SNP 
probes from rs2287273 (chr2: 15658523) to rs6748658 
(chr2: 16145517), and flanked by rs2287272 (chr2: 
15651846) and rs13008990 (chr2: 16150760), the nearest 
probes which detected normal copy number. The region of 
gain contained the complete coding sequences of MYCN 
and DDX1, and the 5’ region of NBAS, and was consistent 
with the focal gains typically observed in WT samples in 
our previous SNP array study [11].
Parallel Evolution of MYCN mutations and copy 
number aberrations in a bilateral WT case
One of the samples in which a P44L mutation 
was detected by exome sequencing was taken from the 
right side of a second bilateral case we have previously 
described [36]. This case is notable for its significant 
intra-tumour heterogeneity on the left side (Figure 2, 
Supplementary Figure 2, Table 2), and for the evolution 
of different anaplasia-associated TP53 mutations in 
each contralateral tumour. We assessed codon 44 status, 
major copy number aberrations, and copy neutral loss 
of heterozygosity (LOH) in multiple samples taken 
at various time points (Table 2). For MYCN, the copy 
number measurements by SNP array were confirmed by 
MLPA (as below) in three samples (ICH 3863, ICH-3864 
and ICH-3865), which gave fully concordant results. Two 
spatially separated samples from the initial right partial 
nephrectomy carried the P44L mutation, and a SNP array 
of one of these indicated normal MYCN copy number. 
There were no MYCN mutations in any other material 
from the right kidney (Table 2), but as previously reported 
[36], this tumour carried a p.I195T mutation in TP53 
at relapse, consistent with its anaplastic histology; high 
quality DNA suitable for copy number analysis was not 
available for the sample at this time point.
In the left kidney, P44 was wild type in all material, 
including 3 tumour samples that carried the previously 
reported contralateral p.V173L mutation in TP53 [36]. 
SNP arrays were available for two of these samples 
and from an initial biopsy (Figure 2); all showed clear 
evidence of MYCN gain. Thus, in the contralateral kidneys 
of a single case with considerable spatial heterogeneity we 
observed separate MYCN aberrations (P44L on the right, 
copy number gain on the left) and distinct TP53 mutations 
(I195T on the right, V173L on the left).
MYCN gain is associated with anaplastic histology 
and poorer outcome
MYCN gain was measured in 293 WT cases 
(Supplementary Table 1) using the P380 Wilms Tumour 
probemix (gain threshold = 1.2, determined empirically 
with reference to Affymetrix and Illumina SNP array data). 
A single sample with copy number loss at the MYCN locus 
was excluded from further analysis. Associations between 
histological subtype and gain were assessed by two-tailed 
Fisher’s exact test. There was no significant association 
(p > 0.05) between histology and MYCN gain for the 
blastemal, epithelial, stromal, mixed, regressive or focal 
anaplastic subtypes. However, for the diffuse anaplastic 
subtype, where 7/23 (30.4%) samples had MYCN gain 
compared to 30/269 (11.2%) in the remaining series, the 
association was significant (p = 0.0159). Survival analyses 
factored by MYCN copy number status (gained / normal) 
were carried out using the Kaplan-Meier model (Figure 3); 
two samples with no outcome data were excluded, and two 
further samples from patients who died without a defined 
relapse event were included in the analyses of overall, but 
not relapse-free, survival. MYCN gain was associated with 
significantly poorer relapse-free (p = 0.005) and overall 
(p = 0.002) survival by the Log Rank (Mantel-Cox) test. 
Using the Cox Proportional Hazards model, we calculated 
the hazard ratios for MYCN gain as 2.443 (relapse) and 
3.545 (death). However, since anaplastic histology is itself 
associated with poor outcome, survival analysis was also 
carried out with the anaplastic samples removed from 
the series (Figure 3). Again, the MYCN gain group had 
significantly poorer relapse-free (p = 0.006) and overall (p 
= 0.003) survival by the Log Rank test, with hazard ratios 
of 2.697 (relapse) and 4.610 (death). 11 of the 37 samples 
with MYCN gain (2p24.3) also had gain of the DYSF locus 
(control probe) on 2p13.3, indicating that MYCN gain is 
not always focal. We therefore determined whether gain 
of DYSF, as an example of a 2p locus that is distinct from 
MYCN, is associated with a particular subtype or outcome, 
using the same analyses we applied to MYCN (excluding 
cases with DYSF loss). There was no association between 
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DYSF gain and any of the histological subtypes, and no 
significant difference between the relapse free or overall 
survival of cases with gained or normal DYSF at the p < 
0.05 level.
MYCN overexpression is associated with 
hypomethylation of specific loci
In a parallel study in our laboratory, we have 
recently completed an integrated genomic analysis of WT 
in which 65 samples were profiled on Affymetrix 250K 
Nsp / SNP 6.0 arrays for copy number, Illumina HT-12 
arrays for mRNA expression, and Illumina 450K arrays 
for DNA methylation (manuscript in preparation). We 
therefore examined these data to determine if there is 
evidence of significant differential regulation of MYCN 
expression in this tumour series. MYCN expression 
levels were assessed in each of six histological subtypes 
(Figure 4, Supplementary Table 2). Levels of expression 
appeared notably higher in the high risk diffuse anaplastic 
(DA) and blastemal type (BT) tumours than in the four 
intermediate risk (IR: epithelial, stromal, mixed and 
regressive type) tumours examined. Univariate class 
comparisons (two-sample t-test) between the IR tumours 
(taken together as a group) and the tumours in either 
of the high risk groups identified MYCN as a relatively 
overexpressed gene in both DA and BT WT. When DA 
tumours were compared with IR tumours at the p < 0.01 
significance level, 1786/34339 (5%) of the probes on 
the array detected differential expression, including both 
probes for MYCN (ILMN_1653761: p = 0.0001, fold-
change 2.10; ILMN_2219767: p = 0.0002, fold-change 
3.34). Similarly, for BT vs IR, 2521/34339 (7%) of probes 
detected differential expression, including both MYCN 
probes (ILMN_1653761: p = 0.0019, fold-change 1.66; 
ILMN_2219767: p = 0.0013, fold-change 2.87). MYCN 
overexpression also appeared to be associated with poorer 
outcome. Applying the Cox proportional hazards model to 
the expression data (Wald statistic, p < 0.01) identified 803 
probes that detected genes in which overexpression was 
associated with poorer relapse-free survival (hazard ratio 
≥ 1.5), including both MYCN probes (ILMN_1653761: p 
= 0.0082, hazard ratio = 1.9; ILMN_2219767: p = 0.0097, 
hazard ratio = 1.5). To establish whether the expression 
patterns we observed were potentially driven by DNA 
methylation events or by copy number changes, we 
carried out Spearman rank correlation analyses across the 
sample series between the expression data (log2 intensity) 
and either the segmented log2 copy number data, or the 
logit-transformed methylation value (M value), using all 
probes with annotation that mapped them to MYCN. By 
Figure 3: Survival analysis in SIOP patients with or without MYCN gain. (a) Relapse-free survival (RFS) in cases of all 
histologies with MYCN gain (blue) or with normal MYCN copy number (green). (b) Overall survival (OAS) in patients of all histologies. (c) 
Relapse-free survival in cases with diffuse anaplasia excluded. (d) Overall survival in cases with diffuse anaplasia excluded.
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this metric we detected only a weak positive correlation 
between MYCN expression and copy number that did not 
quite reach statistical significance (ILMN_1653761: rho = 
0.23, p = 0.0672; ILMN_2219767: rho = 0.24, p = 0.0522). 
However, we detected a strong negative correlation (rho 
= -0.50 to -0.71, p < 0.0001) between MYCN expression 
detected by both probes and methylation level at five 
loci probed by the 450K array (Figure 5). Two of these 
loci (cg20431766 and cg07083806) are in the intron 
downstream of the first MYCN coding exon, and the more 
5’ probe, cg20431766, is within the CpG island that spans 
the MYCN promoter. The other three loci (cg19623054, 
cg04609952, cg25074809) overlap with the second 
coding exon. Although the methylation array includes 
another 18 probes that are annotated to MYCN and either 
overlap with the gene or are located in the intergenic 
region immediately upstream of its start site, none of 
these detected differential methylation that significantly 
correlated with gene expression (Spearman rho < -0.5 or 
> 0.5; p < 0.05). 
DISCUSSION
The results presented here suggest that MYCN 
function in Wilms tumour is potentiated by several 
mechanisms. Copy number gains that included the 
MYCN locus were detected in 37/292 (12.7%) of tumours 
overall, and in 7/23 (30.4%) of diffuse anaplastic WTs. 
Relative overexpression of MYCN is associated with 
hypomethylation of two differentially methylated regions 
within the MYCN gene. 8/213 (3.8%) of samples carried 
a recurrent point mutation, c.131C>T (p.P44L), that has 
been identified in neuroblastoma as an acquired somatic 
variant with presumed gain of function [27]. MYCN 
mutations had not previously been described in WT, but 
during the review of this manuscript another group [37] 
reported two further examples of the P44L mutation. 
We note also that our previous discovery of FBXW7 
aberrations in a small proportion of WTs [11] may 
represent an additional mechanism of MYCN regulation, 
since FBXW7 is part of a ubiquitin ligase complex that 
degrades MYCN.
Our results suggest that MYCN dysregulation is 
significantly associated with adverse outcome. MYCN gain 
was associated with high risk diffuse anaplastic histology, 
and with poorer relapse-free and overall survival, even 
when diffuse anaplastic cases were excluded from the 
analysis. This is consistent with a previous study that 
found an association between MYCN expression and 
relapse [38]. MYCN was relatively overexpressed in 
diffuse anaplastic and blastemal type tumours, and there 
was an association between expression level and poorer 
Figure 5: Illumina 450K methylation probes in the MYCN region. * = locus where expression and methylation are significantly 
correlated.
Figure 4: MYCN expression in Wilms tumour. Box plots of MYCN expression in (a) six SIOP histological WT subtypes and (b) with 
histologies grouped together as high risk or intermediate risk. Values are the mean log2 intensities of expression detected by both Illumina 
HT-12 probes within each subtype: blastemal type (n = 9, high risk), diffuse anaplastic (n = 11, high risk), epithelial type (n = 9, intermediate 
risk), mixed type (n = 17, intermediate risk), regressive type (n = 10, intermediate risk) and stromal type (n = 9, intermediate risk). Focal 
anaplastics were excluded due to insufficient numbers.
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relapse-free survival. However, it is unclear if all potential 
mechanisms of dysregulation have the same functional 
effect on downstream pathways or tumour behaviour. 
The number of P44L mutations detected to date is too 
small to draw firm conclusions about associations with 
outcome or histology. A recurrent somatic variant at a 
single highly conserved residue is most consistent with an 
activating mutation, though it has not yet been subject to 
a full functional analysis in WT or in neuroblastoma. We 
did detect one additional somatic variant, R285W, that is 
predicted to be deleterious, but its exact functional impact 
is currently unknown. Three of the P44L mutations were 
also associated with MYCN copy number gain. This may 
indicate further selection by the tumour cell for multiple 
copies of a variant that confers a growth advantage. 
The case with MYCN mutation in one kidney and 
copy number gain in the other is a striking example of 
parallel evolution in bilateral disease. As we reported 
previously [36], this case also has independent contralateral 
TP53 mutations, albeit with apparently dissimilar timing 
of the mutational events. In the left kidney, MYCN 
gain was detected in all specimens examined (Table 2), 
including the initial pre-chemotherapy biopsy, while the 
V173L TP53 mutation was absent at initial biopsy and 
in a precursor lesion (nephrogenic rest). A copy number 
profile was not available for the nephrogenic rest, so it was 
not possible to determine if MYCN gain was present in 
the earliest phase of tumourigenesis, but it is notable that 
the MYCN aberration, together with the large-scale copy 
number changes on 10p, 20p and 13 that were common to 
all profiled samples, appear to have preceded disruption 
of TP53 by point mutation and 17p loss. In the right 
kidney, both genes were wild type at initial biopsy, but the 
MYCN P44L mutation was detected at the time of the first 
(partial) resection, again before any TP53 aberrations were 
observed. A subsequent relapse, 4 years after the original 
tumour was excised, carried the I195T TP53 mutation, 
concomitant with the development of anaplasia, but the 
MYCN sequence was wild type. It therefore appears that 
similar but independent evolutionary solutions affecting 
two different pathways have been selected for at different 
stages of the development of contralateral tumours in the 
same patient, with MYCN disruption the earlier event on 
each side. We note, however, that interpretation of this 
case is complicated by spatial heterogeneity, which is 
obviously extensive, at least at the copy number level. 
It is, for example, not possible to determine from our 
current analysis whether the relapse in the right kidney, 
which has a novel TP53 mutation but lacks the MYCN 
mutation, arose from some minority clone not sampled or 
undetectable in the first (partial) nephrectomy, or if the 
relapse itself (of which there was only a single sample) 
had developed significant spatial heterogeneity. It is even 
possible that the ‘recurrence’ was a novel primary tumour.
MYCN gain, even when focal, typically also results 
in gain of the adjacent DDX1 gene. All the focal events 
at this locus analysed by SNP arrays in our previous 
study [11] had DDX1 gain, as did the germline gain 
detected here. Recently, a similar region of germline gain 
encompassing both genes was detected in a patient with 
bilateral nephroblastomatosis and a family history of WT 
[39]. A genome-wide association study has also identified 
potential WT susceptibility loci in this commonly gained 
region, mapping to SNPs that flank DDX1 [40]. We cannot 
therefore rule out a significant role for DDX1 in Wilms 
tumour. However, our finding that MYCN is also subject 
to putatively activating point mutations strongly suggests 
that MYCN is a primary target for dysregulation at this 
locus.
 In addition to neuroblastoma and WT, MYCN gain 
or amplification is now emerging as a common aberration 
associated with adverse outcome in multiple paediatric 
malignancies, including rhabdomyosarcoma [26] and 
medulloblastoma [24, 25]. This raises the possibility 
that any novel therapies that target the MYCN pathway 
and prove useful in one of these tumours could be of 
significant value in the others. In WT, anaplastic tumours 
that are metastatic at presentation respond poorly to 
current treatment. While TP53 mutation remains the most 
common aberration in this group of tumours, our finding of 
an association between MYCN gain and anaplasia, as well 
as outcome, makes the MYCN pathway an attractive target 
for further research into new approaches to treatment. 
MATERIALS AND METHODS
Clinical samples
Frozen Wilms tumour samples were obtained 
with informed consent and ethical approval according 
to national regulations from UK, German, Dutch, and 
Swedish centres participating in the SIOP WT 2001 
clinical study and trial (2001-2011) (Supplementary Table 
1). A frozen section was prepared directly or paraffin-
embedded from the same specimen used in nucleic acid 
extraction, stained with haematoxylin and eosin, and 
assessed for tumour content by an experienced paediatric 
pathologist. Only samples from WT cases treated by the 
standard neoadjuvant chemotherapy treatment approach 
were included in this study. 
Nucleic acid extraction
Frozen tumour material was pulverised at 
liquid nitrogen temperatures using a Sartorius Mikro-
Dismembrator. Genomic DNA was prepared by standard 
detergent lysis and phenol-chloroform extraction 
methods. Total RNA was extracted using Trizol reagent 
(Life Technologies) according to the manufacturer’s 
instructions.
Oncotarget7240www.impactjournals.com/oncotarget
Whole exome sequencing
Target enrichment using the Agilent SureSelect 
V4+UTR system and sequencing on the Illumina HiSeq 
2000 instrument were carried out by an external service 
provider. Data were analysed using a somatic variant 
detection pipeline on the UCL Computer Science HPC 
cluster. Sequence reads were aligned to human genome 
build hg19 using BWA [41]. Removal of PCR duplicates, 
local realignment around indels, and quality score 
recalibration were carried out using GATK [42] and Picard 
(http://picard.sourceforge.net/), according to the GATK 
‘best practice’ recommendations. Somatic variants were 
detected with MuTect [43], annotated with ANNOVAR 
[44], and assessed in IGV [45, 46]. All MYCN variants are 
described with reference to the translational start codon 
of NCBI RefSeq cDNA NM_005378.4, corresponding to 
protein NP_005369.2.
PCR and Sanger sequencing
The complete coding sequence of MYCN 
was amplified from genomic DNA using primers: 
Ex2Af: 5’- GGTATTAAAACGAACGGGGC-3’; 
Ex2Ar: 5’-GGACTGGGCGGTGGAAC-3’; Ex2Bf: 
5’- ATCCTCCAGGACTGCATGTG-3’; Ex2Br: 
5’-CAGGCCAAGACATACGAGC-3’; Ex3Af: 
5’- GCCGGAAGAGACAGATAAGC-3’; Ex3Ar: 
5’- GATGTTGTGGTTTCTGCGAC-3’; Ex3Bf: 
5’- CCACCAGCAGCACAACTATG-3’; Ex3Br: 
5’-TACTGCCCACCCAGAGCC-3’. PCR products 
were sequenced using the ABI BigDye cycle sequencing 
kit on an ABI Prism 3100 Genetic Analyzer. Variants 
were detected and assessed with GeneScreen [47] with 
reference to the hg19 reference sequence.
MLPA
MLPA was performed according to the 
manufacturer’s instructions using the P380 Wilms Tumour 
probemix, developed by MRC-Holland in association 
with our laboratory. This probemix includes 3 probes for 
MYCN, a DYSF control probe on 2p outside the common 
region of genomic gain previously observed on SNP 
arrays, a PAX3 control probe on 2q, further test probes to 
other loci of interest in the Wilms tumour genome, and 
9 reference probes to loci on chromosomes 3, 5, 15, 19 
and 21 found to have comparatively stable copy number 
in previous Wilms tumour microarray experiments. 
Since MYCN binding sites are distributed throughout the 
genome, we reasoned that the most biologically relevant 
measurement of MYCN status was its copy number relative 
to the genomic baseline copy number. All copy number 
measurements were therefore made with respect to the 
9 reference probes; the DYSF and PAX3 probes served 
only to determine whether any MYCN gain observed was 
in the context of larger scale gain of 2p or of the whole 
chromosome.
Methylation arrays
DNA methylation profiling was carried out 
according to the manufacturer’s instructions using 
the Zymo EZ DNA Methylation kit kit and Illumina 
Infinium HumanMethylation450 BeadChip. Arrays were 
run and scanned at the UCL Genomics ICH Microarray 
facility. Data were normalised and analysed using the 
Bioconductor [48] packages minfi [49] and limma [50].
Expression arrays
Expression profiling was carried out on the Illumina 
HumanHT-12 v3 Expression BeadChip at the UCL 
Genomics ICH Microarray facility, according to the 
manufacturer’s instructions. Data were normalised and 
analysed using the lumi [51] Bioconductor package and 
BRB-ArrayTools [52].
SNP arrays
DNA samples were profiled on Affymetrix Human 
Mapping 250K Nsp or Genome-Wide Human SNP Array 
6.0 arrays at UCL Genomics, UK or AROS Applied 
Biotechnology A/S, Denmark. Copy number and LOH 
analysis was carried out using the Affymetrix Genotyping 
Console, using HapMap reference samples, and visualised 
in CGH Explorer [53] or IGV [45, 46]. Samples from a 
single case with germline MYCN gain were profiled on 
the Illumina HumanCytoSNP-12 BeadChip, and analysed 
with Illumina GenomeStudio and OncoSNP [54]. Raw 
data are available from the authors on request.
Survival analysis
Survival analyses were carried out in IBM SPSS 21 
using the Kaplan-Meier model, with the Log Rank test for 
equality of the survival distributions. Hazard ratios were 
determined using the Cox Proportional Hazards model.
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